Biotech Funding Concentrates in Fewer, Larger Rounds

- While total biopharma venture funding rebounded in 2024 to between $21.4 billion and $26.0 billion, surpassing pre-pandemic levels, the number of deals declined. Mega-rounds exceeding $100 million now constitute two-thirds of all venture funding, a significant increase from 35% before the pandemic. - The IPO market remains challenging, drastically constricting a key exit path for investors and forcing companies to seek later-stage private funding instead. In the first three quarters of 2023, only 30 biotechs went public, a steep drop from 114 during the same period in 2021. - Funding for discovery and preclinical-stage companies has been hit particularly hard, with total IPO value for this segment dropping four-fold from $490.6 million in 2023 to $112.5 million in 2024. This indicates a clear investor preference for companies with assets that are already in or approaching clinical trials. - Nearly 30% of all U.S. healthcare venture funding in 2024 was directed toward companies enabled by artificial intelligence. Spending on AI in the pharmaceutical industry is projected to reach $3 billion by 2025, as it is seen as critical for improving R&D efficiency and reducing drug development timelines. - The challenging environment has forced operational changes, with over 250 biotech companies initiating layoffs and streamlining pipelines in 2022 and 2023 to conserve cash. More than half of all publicly traded biotechs ended 2024 with a cash runway of less than two years. - Cell and gene therapy manufacturing remains a key investment area, exemplified by ElevateBio's $401 million Series D round in 2023 to expand its technology platforms and manufacturing business. Similarly, gene therapy company Kriya Therapeutics raised $320 million in a Series D round in 2025 to advance its clinical pipeline.